Nordic Life Science 1
n 2001 the brand name Recipharm was established f
or the growing contract manufacturing part of the business. Fast forward to today and the company, still with its headquarters in Sweden, includes around 30 manufacturing and development facilities globally. It currently has a unique position as one of the top five global CDMO (Contract Development and Manufacturing Organization) in the pharma industry. ”Whilst there are several companies offering development or commercial only services, there are very few offering end-to-end services from development to commercialization of pharmaceuticals, and in particular with concurrent inhalation and autoinjector devices,” says Eldered. The road towards becoming one of the top five CDMOs in the world has included a lot of acquisitions, adding new technologies, more diverse dosage forms, and new customers. Between 2001 and 2007 six facilities were acquired. In 2007 outsourcing had become a priority and the company decided to focus fully on the outsourcing business. Rights to products were sold and the company’s position as a pure CDMO was established. began in 1995 with the buyout of a solid dose facility in Stockholm, performed by two employees of the selling company, Thomas Eldered and Lars Backsell. Eldered had knowledge of manufacturing and of the facility and Backsell had market and product development experience. The facility included a portfolio of around 20 established pharmaceutical products and the new company began its development. ”Over the past 25 years, Recipharm has grown a considerable amount, not only in terms of employees but also when it comes to our culture, customers, and service offering. It is a little surreal to think back to 1995, when we were first known as Recip. Back then we just focused on making the most of the opportunities we had, there and then,” says Thomas Eldered, CEO and co-founder of Recipharm. ecipharm was listed on the Stockholm Stock Exchange in April 2014, and in the same year it made three important acquisitions, the Milano based Corvette Pharmaceutical Services Group, Portugese CMDO Lusomedicamenta Sociedade Técnica Farmacêutica S.A and a Flamel Technologies development facility in Pessac, France.